Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Altimmune, Inc. | alt-ex322_11.htm |
| EX-32.1 - EX-32.1 - Altimmune, Inc. | alt-ex321_7.htm |
| EX-31.2 - EX-31.2 - Altimmune, Inc. | alt-ex312_9.htm |
| EX-31.1 - EX-31.1 - Altimmune, Inc. | alt-ex311_8.htm |
| EX-21 - EX-21 - Altimmune, Inc. | alt-ex21_6.htm |
| EX-4.10 - EX-4.10 - Altimmune, Inc. | alt-ex410_379.htm |
| 10-K - 10-K - Altimmune, Inc. | alt-10k_20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
Form |
Registration Number |
Date Filed |
|
S-8 |
333-233273 |
8/14/2019 |
|
S-3 |
333-230723 |
4/4/2019 |
|
S-8 |
333-230722 |
4/4/2019 |
|
S-8 |
333-228623 |
11/30/2018 |
|
S-3 S-8 S-8 S-8
|
333-217034 333-217846 333-214765 333-156371
|
3/30/2017 5/10/2017 11/22/2016 12/19/2008
|
of our report dated March 27, 2020, with respect to the consolidated financial statements of Altimmune, Inc., included in this Annual Report (Form 10-K) of Altimmune, Inc. for the year ended December 31, 2019.
|
/s/ Ernst & Young LLP |
|
|
|
|
|
Baltimore, Maryland |
|
|
March 27, 2020 |